Crinetics Pharmaceuticals Inc (CRNX)

$43.44 -0.56 (-1.27%)
Market Cap 4.50B
Revenue (ttm) 1.04M
Net Income (ttm) -298.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,693.27%
Debt to Equity Ratio 0.00
Volume 930,000
Avg Vol 1,234,256
Day's Range N/A - N/A
Shares Out 102.17M
Stochastic %K 22%
Beta 0.19
Analysts Strong Sell
Price Target $85.00

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 450 6464
Address:
6055 Lusk Boulevard, San Diego, United States
CapitalRadiance
CapitalRadiance Feb. 20 at 2:12 PM
$CRNX Crinetics Pharmaceuticals develops endocrine disorder therapies. Clinical execution drives valuation. Cash runway supports development.
0 · Reply
NettyLite
NettyLite Feb. 18 at 10:40 AM
$CRNX a very special robot friend told me to buy this
0 · Reply
CH_Expat
CH_Expat Feb. 18 at 9:49 AM
$CRNX Baker Bros bought in heavily here as per their latest filing!
0 · Reply
SpectralWick
SpectralWick Feb. 18 at 9:03 AM
$CRNX Specialty pharma with binary trial risk; valuation resets quickly after regulatory milestones.
0 · Reply
CDMO
CDMO Feb. 13 at 7:42 PM
$CRNX what a beating!
1 · Reply
ZManicItalian
ZManicItalian Feb. 13 at 7:21 PM
$CRNX buy at $40 🤔
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 12 at 12:11 PM
$CRNX Share Price: $47.61 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $10.48 – $12.95 Target Zone: $17.25 – $21.09 Potential Upside: 55% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CDMO
CDMO Feb. 6 at 8:11 PM
$CRNX price getting more tempting. Below 40 i am back
1 · Reply
CH_Expat
CH_Expat Feb. 4 at 12:48 PM
$NVO With the new EVP having a endocrine and metabolism focus, they might acquire $NBIX or $CRNX .
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 2 at 3:08 PM
$CRNX Share Price: $50.27 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $6.21 – $7.67 Target Zone: $10.38 – $12.69 Potential Upside: 58% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on CRNX
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Feb 5, 2026, 4:05 PM EST - 15 days ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 26, 2026, 5:00 PM EST - 25 days ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 22, 2026, 4:05 PM EST - 4 weeks ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 3:56 PM EST - 5 weeks ago

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 4:05 PM EST - 5 weeks ago

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 6, 2026, 9:22 PM EST - 6 weeks ago

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 5, 2026, 4:02 PM EST - 6 weeks ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript

Jan 5, 2026, 1:27 PM EST - 6 weeks ago

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Jan 5, 2026, 8:00 AM EST - 6 weeks ago

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Jan 4, 2026, 4:00 PM EST - 6 weeks ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 4:05 PM EST - 2 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Dec 11, 2025, 4:05 PM EST - 2 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2025, 4:34 PM EST - 2 months ago

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Dec 3, 2025, 8:00 AM EST - 2 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Nov 20, 2025, 4:05 PM EST - 3 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 4:28 PM EST - 3 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 12:46 PM EST - 3 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Oct 23, 2025, 8:00 AM EDT - 4 months ago

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:41 PM EDT - 4 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 6, 2025, 4:05 PM EDT - 4 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating

Sep 26, 2025, 5:00 PM EDT - 5 months ago

Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating

Crinetics Pharmaceuticals, Inc. - Special Call

Sep 26, 2025, 1:57 AM EDT - 5 months ago

Crinetics Pharmaceuticals, Inc. - Special Call

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Sep 25, 2025, 5:30 PM EDT - 5 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:30 PM EDT - 5 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Aug 21, 2025, 8:45 AM EDT - 6 months ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 11, 2025, 4:05 PM EDT - 6 months ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 11:21 AM EDT - 6 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Jul 13, 2025, 5:45 PM EDT - 7 months ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 11, 2025, 8:00 AM EDT - 8 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 4:28 PM EDT - 8 months ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Jun 30, 2025, 4:05 PM EDT - 8 months ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Jun 16, 2025, 8:00 AM EDT - 8 months ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:29 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

May 23, 2025, 8:00 AM EDT - 9 months ago

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

May 15, 2025, 4:05 PM EDT - 10 months ago

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025, 4:05 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

May 10, 2025, 1:50 PM EDT - 10 months ago

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 10 months ago

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 11, 2025, 8:00 AM EDT - 11 months ago

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 10, 2025, 5:04 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Apr 2, 2025, 2:15 PM EDT - 11 months ago

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Mar 27, 2025, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 10, 2025, 4:36 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:01 PM EST - 1 year ago

Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Feb 24, 2025, 8:30 AM EST - 1 year ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Feb 20, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 10, 2025, 4:44 PM EST - 1 year ago

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CapitalRadiance
CapitalRadiance Feb. 20 at 2:12 PM
$CRNX Crinetics Pharmaceuticals develops endocrine disorder therapies. Clinical execution drives valuation. Cash runway supports development.
0 · Reply
NettyLite
NettyLite Feb. 18 at 10:40 AM
$CRNX a very special robot friend told me to buy this
0 · Reply
CH_Expat
CH_Expat Feb. 18 at 9:49 AM
$CRNX Baker Bros bought in heavily here as per their latest filing!
0 · Reply
SpectralWick
SpectralWick Feb. 18 at 9:03 AM
$CRNX Specialty pharma with binary trial risk; valuation resets quickly after regulatory milestones.
0 · Reply
CDMO
CDMO Feb. 13 at 7:42 PM
$CRNX what a beating!
1 · Reply
ZManicItalian
ZManicItalian Feb. 13 at 7:21 PM
$CRNX buy at $40 🤔
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 12 at 12:11 PM
$CRNX Share Price: $47.61 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $10.48 – $12.95 Target Zone: $17.25 – $21.09 Potential Upside: 55% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CDMO
CDMO Feb. 6 at 8:11 PM
$CRNX price getting more tempting. Below 40 i am back
1 · Reply
CH_Expat
CH_Expat Feb. 4 at 12:48 PM
$NVO With the new EVP having a endocrine and metabolism focus, they might acquire $NBIX or $CRNX .
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 2 at 3:08 PM
$CRNX Share Price: $50.27 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $6.21 – $7.67 Target Zone: $10.38 – $12.69 Potential Upside: 58% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 30 at 2:41 PM
$CRNX Share Price: $52.44 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $10.48 – $12.95 Target Zone: $17.35 – $21.21 Potential Upside: 56% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Jan. 27 at 1:20 PM
$CRNX $NBIX Consolidated View: Market is big enough for both. $NBIX = Standard of Care for the masses. $CRNX = The 'Heavy Lift' for severe cases & TARTs. Watch for 'Clinical Superiority' designation for $CRNX to bypass orphan exclusivity. That is the key regulatory unlock. Read more: www.clinicaltrialsdaily.com/mc2r-antagonism-refractory-cah-potency/
1 · Reply
BioTechHealthX
BioTechHealthX Jan. 25 at 4:46 PM
$CRNX Not every biotech needs fireworks on day one. Crinetics Pharmaceuticals (NASDAQ:CRNX) is building steady value in endocrine diseases—and CRNX stock reflects that patience. https://biotechhealthx.com/biotech-news/why-crinetics-pharmaceuticals-crnx-is-the-slow-burn-biotech-investors-love/
0 · Reply
TipRanks
TipRanks Jan. 16 at 11:10 AM
‘Markets Climb Wall-of-Worry’: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy https://www.tipranks.com/news/article/markets-climb-wall-of-worry-oppenheimer-sees-resilience-driving-2026-and-suggests-2-stocks-to-buy $AMPX $CRNX
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 11:07 AM
$CRNX Current Stock Price: $55.48 Contracts to trade: $55 CRNX Jan 16 2026 Call Entry: $1.53 Exit: $2.42 ROI: 58% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
RunnerSignals
RunnerSignals Jan. 13 at 7:46 PM
$OPRT $VIST $CRNX $NFLX $RDDT Analyst upgrades are flying! Which stock could blast off first? Traders are buzzing, don't miss the action! https://stocksrunner.com/news/2026-01-13-stock-upgrades-today-reveal-top-buy
0 · Reply
erevnon
erevnon Jan. 12 at 6:31 PM
Goldman Sachs upgrades Crinetics Pharmaceuticals $CRNX from Neutral to Buy and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
notreload_ai
notreload_ai Jan. 12 at 12:41 PM
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for $CRNX and $FULC , citing clearer paths to success and upside potential. https://notreload.xyz/goldman-jpmorgan-turn-bullish-on-crnx-and-fulc/
0 · Reply
GettnFibbywIT
GettnFibbywIT Jan. 11 at 8:31 AM
$CRNX $QQQ
0 · Reply
IN0V8
IN0V8 Jan. 8 at 4:48 PM
$CRNX Buy Leerink Partners raises PT to $92 from $88
0 · Reply
Spicy_Trade
Spicy_Trade Jan. 8 at 5:38 AM
Crinetics Pharmaceuticals, Inc. ( $CRNX ) daily stock analysis by SpicyT... https://youtu.be/tSNWka4Nsao?si=oeH41o0coxqTc-97
0 · Reply
Bogy99
Bogy99 Jan. 7 at 10:25 PM
$ARWR $CRNX is a good example of what you should expect tomorrow with this. Both companies did the ole price the next day garbage. You have the demand, price it that night. Hopefully nobody sold today. Upwards and onwards.
0 · Reply